Trials / Completed
CompletedNCT00517309
Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)
Immunogenicity and Safety of Quadrivalent HPV L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women When Administered Alone or Concomitantly With Hepatitis B Vaccine (Recombinant)--the F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,877 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 16 Years – 23 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of the study is to test the safety of HPV Vaccine in Women
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years | |
| BIOLOGICAL | Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years |
Timeline
- Start date
- 2001-12-28
- Primary completion
- 2004-06-08
- Completion
- 2004-06-11
- First posted
- 2007-08-16
- Last updated
- 2017-03-22
Source: ClinicalTrials.gov record NCT00517309. Inclusion in this directory is not an endorsement.